37LBA Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial). (September 2015) - Kulke, M.H.; Horsch, D.; Caplin, M.; Anthony, L.; Bergsland, E.; Oberg, K.; Welin, S.; Warner, R.; Lombard-Bohas, C.; Kunz, P.; Grande, E.; Valle, J.; et al.